Research programme: ARRDC1-mediated microvesicles therapeutics - Vesigen Therapeutics
Alternative Names: ARMMs therapeutics - Vesigen TherapeuticsLatest Information Update: 28 Aug 2024
At a glance
- Originator Vesigen Therapeutics
- Class Antineoplastics; Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Eye disorders; Neurological disorders
- No development reported Cancer